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Objective. This systematic review aims to evaluate the beneﬁt and side eﬀect of Xuezhikang for coronary heart disease (CHD)
complicated by dyslipidemia. Methods. All randomized clinical trials (RCTs) with Xuezhikang as a treatment for CHD combined
with dyslipidemia were considered for inclusion. Data extraction and analyses and quality assessment were conducted according
to the Cochrane standards. Results. We included 22 randomized trials. Xuezhikang showed signiﬁcant beneﬁt on the incidence
of all-cause deaths, CHD deaths, myocardial infarction, and revascularization as compared with placebo based on conventional
treatmentforCHD.Itremarkablyloweredtotalcholesterol(TC),triglyceride(TG),andlow-densitylipoprotein-cholesterol(LDL-
C) as compared with the placebo or inositol nicotinate group, which was similar to statins group. Xuezhikang also raised high-
density lipoprotein cholesterol (HDL-C) compared to placebo or no intervention, which was similar to Inositol nicotinate and
slightly inferior to statins. The incidence of adverse events did not diﬀer between the Xuezhikang and control group. Conclusions.
Xuezhikang showed a comprehensive lipid-regulating eﬀect and was safe and eﬀective in reducing cardiovascular events in CHD
patients complicated by dyslipidemia. However, more rigorous trials with high quality are needed to give high level of evidence.
1.Introduction
Coronaryheartdisease(CHD)isoneofthemostseriousdis-
eases with high incidence and mortality. Dyslipidemia con-
tributes greatly to the formation and progression of athero-
sclerosis (AS), which plays a dominant role in leading to
CHD. Patients with CHD are also commonly complicated
with dyslipidemia. Modulating dyslipidemia actively, espe-
cially lowering low-density lipoprotein-cholesterol (LDL-C)
by statins, has been demonstrated to be very crucial to
prevent AS and reduce the morbidity and mortality of CHD.
Most recently, the updated ESC/EAS guidelines for man-
agement of dyslipidemia [1] further highlighted the aggres-
sive lipid-lowering strategy in subjects with documented
coronary vascular disease (CVD) or previous myocardial
infarction (MI). However, the application of statins might
be restricted by the adverse eﬀect on the liver function and
creatine kinase, especially in patients with old age, multiple
comorbiddiseases,high-dosestatins,oracombinationlipid-
lowering therapy. Thus it is of great clinical signiﬁcance to
ﬁndaneﬀectivebutsaferalternativetherapyinCHDpatients
complicated by dyslipidemia.
Xuezhikang is a partially puriﬁed extract of fermented
red yeast rice (Monascus purpureus). It is composed of 13
kinds of natural statins, unsaturated fatty acids, ergosterol,
aminoacids,ﬂavonoids,alkaloid,traceelement,andsoforth.
The health enhancing qualities of this yeast have been in-
troduced and used in China for over two thousand years.
At latest systematic review indicated the beneﬁcial eﬀects
of Xuezhikang in the treatment of hyperlipidemia [2].
Therefore, Xuezhikang has been recommended in a guide-
line for China adult dyslipidemia prevention [3]. Recently,
clinical beneﬁts of Xuezhikang were also found in CHD
patients combined with dyslipidemia in some randomized
controlled trials [4–6]. This systematic review aims to
evaluate the beneﬁt and side eﬀect of Xuezhikang, a potential2 Evidence-Based Complementary and Alternative Medicine
Table 1: Deﬁnition of dyslipidemia or treatment goal of patients with CHD or equivalents on serum lipid level.
Orgination Deﬁnition of dyslipidemia or treatment goal of Patients with CHD or equivalents on serum lipid level
ATP I 1988 [14]
Ideal lipid level: TC < 5.17mmol/L (200mg/dL); LDL-C < 3.36mmol/L (130mg/dL). Patients with
HDL-C < 0.9mmol/L (35mg/dL) were deﬁned unmoral. The deﬁnition of dyslipidemia was
according to the level of LDL-C
ATP II 1993 [15] Treatment goal: LDL-C  2.6mmol/L (100mg/dL)
Ministry of Health of the People’s
Republic of China 1993 [8] The treatment goal was not introduced
CADPS 1997 [16] Treatment goal: TC < 4.68 mmol/L (180mg/dL); TG < 1.7mmol/L (150mg/dL);
LDL-C < 2.6mmol/L (100mmol /L)
ATP III 2001 [17] Treatment goal: LDL-C < 2.6mmol/L (100mg/dL)
Implication of ATP III 2004 [18] Treatment goal: LDL-C < 2.6mmol/L (100mg/dL); the optional goal: LDL-C < 1.8mmol/L
(70mg/dL)
AHA/ACC Guideline 2006 [19] Treatment goal: LDL-C < 2.6mmol/L (100mmol/L), and it is seasonal for lower than 1.8mmol/L
(70mg/dL)
CADPG 2007 [3]
Treatment goal: TC < 4.14mmol/L (160mg/dL) and LDL-C < 2.59mmol/L (100mg/dL) for CHD or
equivalents
Treatment goal: TC < 3.11mmol/L (120mg/dL); LDL-C < 2.07mmol/L (80mg/dL) for ACS or
ischemic cardiovascular disease complicated with diabetes mellitus
Suitable scope of HDL-C: 1.04mmol/L (40mg/dL); suitable scope of TG: <1.7mmol/L
(150mg/dL)
ESC/EAS 2011 [1]
In patients at very high CV risk (established CVD, type 2 diabetes, type I diabetes with target organ
damage, moderate to severe CKD or a score level  10%), the LDL-C goal is <1.8mmol/L
(70mg/dL) and/or 50% LDL-C reduction when target level cannot be reached (I A
recommendation)
alternative drug of statins, for CHD patients complicated by
dyslipidemia, and thus provide further evidence for clinical
application.
2. Methods
2.1. Inclusion Criteria. Randomized controlled trials (RCTs)
comparing Xuezhikang with placebo, no intervention, or es-
tablished lipid-lowing agents in English or Chinese were
considered. Quasirandomized trials were excluded, and the
durationoftheinterventionwasnolessthanfourweeks.Par-
ticipants of all age with CHD complicated by dyslipidemia
meeting with at least one of the current or past deﬁnitions
or guidelines of CHD [including acute coronary syndrome
(ACS)] [7–13] and dyslipidemia (treatment goal as the lower
limit, see Table 1)[ 14–20] were considered. Those who did
not introduce diagnostic criteria in the text but stated pa-
tients with deﬁnite CHD or dyslipidemia were also included.
Secondary dyslipidemia, high serum lipid level after meal,
serious heart failure, and serious hepatic or renal failure were
excluded.
Outcomemeasuresincludeprimaryoutcomes(including
all-cause mortality, CHD mortality, incidence of MI, revas-
cularization, and rehospitalization for unstable angina) and
secondaryoutcomes[includingserumtotalcholesterol(TC),
triglyceride (TG), LDL-C, and-high density lipoprotein cho-
lesterol (HDL-C)].
2.2. Search Strategy. Two reviewers searched the following
databases up to September 2011 independently for the
identiﬁcations of trials (publication or nonpublication): The
Cochrane Library, Pubmed, Chinese Biomedical Database
(CBM), China National Knowledge Infrastructure (CNKI),
ChineseVIPInformation(VIP),andWanfangDatabases.We
used the terms as follows: coronary heart disease, CHD, cor-
onary artery disease, angina pectoris, myocardial infarction,
acute coronary syndrome, cardi∗, and Xuezhikang, red yeast
rice,monascus.Becauseofdiﬀerentcharacteristicsofvarious
databases, MeSH terms and free text terms were used regard-
less of the report types in full text, title, keyword, subject
terms, or abstract.
2.3. Data Extraction and Quality Assessment. Two reviewers
(Shang QH, Liu ZL) independently extracted data according
to a data extraction form made by the authors. Disagree-
ments were resolved by consensus or consultation from
a third reviewer (Liu JP). The methodological quality of
trials was assessed independently using criteria from the
Cochrane Handbook for Systematic Review of Interventions,
Version 5.0.1 (Shang QH, Liu ZL) [20]. We contacted with
the authors if there was any doubt in randomization and
blinding method. The items included random sequence gen-
eration (selection bias), allocation concealment (selection
bias), blinding of participants and personnel (performance
bias), blinding of outcome assessment (detection bias), in-
complete outcome data (attrition bias), selective reporting
(reporting bias), and other bias. We judged each item from
three levels (“Yes” for a low of bias, “No” for a high risk of
bias, “Unclear” otherwise), and then we assessed the trials
and categorized them into three levels: low risk of bias (all
the items were in low risk of bias), high risk of bias (at leastEvidence-Based Complementary and Alternative Medicine 3
CBM VIP Wanfang CNKI Pubmed The cochrane 
library
Records after 
duplicates remove
Full-text articles assessed
for eligibility
Records excluded  Screening the 
title and abstract
22 trials (23 papers)
included in the 
review
157 articles excluded with reasons
       listed as the following.
￿ No data for extraction 
Data unavailable 
Screening the 
full text
(n = 258) (n = 80) (n = 169) (n = 281) (n = 36) (n = 55)
(n = 545)
(n = 363)
(n = 183)
(n = 1)
￿ No random (n = 2)
￿ Duplication (n = 32)
￿ No control group (n = 5)
￿ Not randomized clinical 
trial (n = 3)
￿ The intervention included 
Chinese herbla medicine 
(n = 2)
(n = 2)
￿ Number of the two groups 
was not clear (n = 1)
￿ The participants did not 
meet the inclusive criteria 
(n = 112)
Figure 1: Flow chart of study selection.
oneitemwasinhighriskofbias),unclearriskofbias(atleast
one item was in unclear).
2.4. Data Synthesis. We used Revman 5.1 software provided
by the Cochrane Collaboration for data analyses. Studies
were stratiﬁed by the types of comparisons. We will express
dichotomous data as risk ratio (RR) and its 95% conﬁdence
intervals (CI). Continuous outcome will be presented as
mean diﬀerence (MD) and its 95% CI. Heterogeneity was
recognized signiﬁcant when I2  50%. Fixed eﬀects model
was used if there is no signiﬁcant heterogeneity of the data;
random eﬀects model was used if signiﬁcant heterogeneity
existed (50% <I 2 < 85%). Publication bias was explored us-
ing a funnel plot.
3. Results
3.1. Description of Included Trials. 22 RCTs (23 papers) [4–6,
21–39] were included, 21 papers were published in Chinese,
one paper published in English, and one was unpublished as
a postgraduate dissertation. The whole process of trials se-
lection was demonstrated in Figure 1. The characteristics of
included trials were listed in Table 2.
6520 Participants were included (3264 in intervention
group and 3256 in control group). Two of the trials did not
report the gender, and 4905 male and 1538 female were in-
cluded in the other 20 trials. A total of 7 criteria of CHD
(including ACS) were selected, but 6 trials did not introduce
criteria of CHD but mentioned “patients with CHD were
eligible to include.” 3 criteria of dyslipidemia were used for
11 trials, and the other 11 trials only reported the serum lipid
levels, which were categorized to dyslipidemia according to
the previous and current deﬁnitions and guidelines Table 1.
One trial [4] included patients with MI; ﬁve of the trials
[5,27,28,34,39]includedpatientswithunstableangina;two
of the trials [6, 38] included patients with ACS; three of the
trials [21, 22, 31] included patients with stable angina. The
other 11 trials [23–26, 29, 30, 32, 33, 35–37] did not intro-
duce the types of CHD or all types were included.
Patients in 19 trials prescribed Xuezhikang 600mg QD
(regulation was conducted for adverse events), one trial used
Xuezhikang 600mg TID if the serum TC or TG still higher4 Evidence-Based Complementary and Alternative Medicine
after having been prescribed for 6 weeks (600mg BID in
previous 6 weeks) [30], one trial [37] prescribed Xuezhikang
300mg TID, and one trial [31] prescribed Xuezhikang
1200mgQN.Thedurationoftreatmentrangedfrom4weeks
to 7 years.
There were ﬁve comparisons in the review according to
various control groups. (1) Xuezhikang and conventional
therapy versus conventional therapy (8 trials) [5, 6, 24, 29,
33, 34, 38, 39]; (2) Xuezhikang and conventional therapy
versusplaceboandconventionaltherapy(2trials)[4,35];(3)
Xuezhikang and conventional therapy versus statin and con-
ventional therapy (9 trials) [21–23, 25, 26, 28, 31, 37, 39]; (4)
Xuezhikangandstatinandconventionaltherapyversusstatin
and conventional therapy (2 trials) [27, 36]; (5) Xuezhikang
and aspirin versus inositol nicotinate and aspirin (1 trials)
[32]. One trial [39] was designed as three groups with
two comparisons and Xuezhikang and conventional therapy
versus conventional therapy; Xuezhikang and conventional
therapy versus atorvastatin and conventional therapy.
3.2. Methodological Quality of Included Trials. According to
the criteria introduced above, no trial was evaluated as hav-
ing a low risk of bias. Only one trial of the 22 trials reported
the method to generate the allocation sequence (random
number table) in the paper [6]. After we contacted with the
authors, six trials announced a correct method for allocation
sequence [4–6, 31, 33, 35]. One trial was assessed as having
adequate concealment [35]. Two trials applied double-
blinding [4, 35], and two trials used single-blinding but did
give us objective to be blinded [25, 37]. One trial blinded the
outcome assessors [4]. One trial reported prior sample size
estimation and mentioned intention-to-treat analysis [4].
Five trials reported information on withdrawal/dropout [4,
6, 22, 29, 32]. 18 trials [4–6, 22–27, 29, 31–33, 35–39]
provided baseline data for the comparability among groups.
The results of the assessment of risk of bias are presented in
a “risk of bias summary” ﬁgure produced by Revman 5.1 au-
tomatically Figure 2.
3.3. Eﬀect Estimates of Outcomes (Tables 3 and 4)
3.3.1.All-CauseMortality. Therewasonly1trial[4]reported
the all-cause mortality in the comparisons of Xuezhikang
and conventional therapy versus placebo and conventional
therapy [RR 0.67; 95% CI 0.54 to 0.83; 1 trial, n = 4870].
3.3.2. Mortality of CHD. There were 5 studies [4, 22, 27,
28, 32] that presented the eﬀect of Xuezhikang in reducing
the mortality of CHD. Compared to placebo on the basis of
conventional therapy, Xuezhikang showed a reduction of
mortality of CHD (RR 0.69; 95% CI 0.54 to 0.89; 1 trial,
n = 4870) [4]. Compared to simvastatin on the basis of
conventional therapy, Xuezhikang showed no signiﬁcant
diﬀerence in mortality of CHD (RR 0.26; 95% CI 0.06 to
1.21; 2 trial, n = 220) [22, 28]. Compared to no treat-
ment on the basis of simvastatin and conventional therapy,
Xuezhikang showed no eﬀect in reducing mortality of CHD
(RR 0.33; 95% CI 0.01 to 7.80; 1 trial, n = 48) [27].
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Compared with inositol nicotinate on the basis of aspirin,
Xuezhikang showed no signiﬁcant diﬀerence in mortality of
CHD (RR 0.15; 95% CI 0.02 to 1.18; 1 trial, n = 122) [32].
3.3.3. Incidence of MI. There were 3 studies reporting CHD
events in 3 diﬀerent comparisons. Compared with placebo
on the basis of conventional therapy, Xuezhikang showed a
reduction of morbidity of MI (RR 0.39; 95% CI 0.28 to 0.55;
1t r i a l ,n = 4870) [4]. Compared with simvastatin on the
basis of conventional therapy, Xuezhikang showed no sig-
nificant diﬀerence (RR 0.95; 95% CI 0.30 to 3.05; 1 trial, n =
84) [28]. In comparisons of Xuezhikang and simvastatin and
conventional therapy versus simvastatin and conventional
therapy, Xuezhikang showed no eﬀect in reducing incidence
of MI (RR 0.20; 95% CI 0.01 to 3.96; 1 trial, n = 48) [27].
3.3.4. Revascularization. Revascularization included percu-
taneous coronary intervention (PCI) and coronary artery
bypass graft (CABG). There were 2 studies [4, 28] reporting
revascularizationin2diﬀerentcomparisons.Comparedwith
placebo on the basis of conventional therapy, Xuezhikang
showed a signiﬁcant reduction of revascularization (RR 0.67;
95% CI 0.50 to 0.89; 1 trial, n = 4870) [4]. Compared with
simvastatin on the basis of conventional therapy, Xuezhikang
showed no signiﬁcant diﬀerence (RR 1.14; 95% CI 0.38 to
3.46; 1 trial, n = 84) [28].
3.3.5. Rehospitalization for Unstable Angina. There were 2
trials [27, 28] reporting rehospitalization in 2 diﬀerent com-
parisons. Compared with simvastatin on the basis of conven-
tional therapy, Xuezhikang showed no signiﬁcant diﬀerence
in the number of rehospitalization (RR 1.02; 95% CI 0.57 to
1.84; 1 trial, n = 84) [28]. Compared with no treatment
on the basis of simvastatin and conventional therapy,
Xuezhikang showed no eﬀect in reducing rehospitalization
(RR 0.20; 95% CI 0.03 to 1.59; 1 trial, n = 48) [27].
3.3.6. Serum TC Level. There were 21 studies that reported
the level of total cholesterol Table 4, but one trial only re-
ported the serum lipid level of the treatment group [30]. (1)
Compared to no treatment with cointervention of conven-
tional therapy, Xuezhikang showed a reduction of TC level
(MD −0.97mmol/L; 95% CI −1.24 to −0.71; 8 trials, n =
500) [5, 6, 24, 29, 33, 34, 38, 39]. (2) There were two trials
that reported Xuezhikang versus placebo on the basis of con-
ventional therapy, meta-analysis was not used for signiﬁcant
diﬀerence, and, in this comparison, Xuezhikang showed a
r e d u c t i o no fT Cl e v e l( M D−0.57mmol/L; 95% CI −0.61 to
−0.53; 1 trial, n = 4870) [4] and (MD −2.62mmol/L; 95%
CI −2.98 to −2.26; 1 trial, n = 62) [35]. (3) There was no
signiﬁcant diﬀerence on serum TC level of Xuezhikang com-
paring to statins on the basis of conventional therapy (MD
0.19mmol/L;95%CI −0.22to0.59;8trial,n = 633)[21,23–
25, 28, 31, 37, 39]. Since there was signiﬁcant heterogeneity
inthecomparison,weexaminedthedatacarefullyandfound
that data of two trials deviated from the others. After looking
over the papers, one of the two trial [26] with an unclear
conventional therapy and the other used Xuezhikang 300mg
tid in the whole trial [37]. Sensitive analysis was used and
got a similar conclusion (MD 0.02mmol/L; 95% CI −0.03 to
0.06; 6 trial, n = 489) after excluded the two trials [26, 37].
(4) Compared with no treatment on the basis of statins and
conventional therapy, Xuezhikang showed a reduction of TC
level (MD −0.96mmol/L; 95% CI −1.33 to −0.58; 2 trial,
n = 108) [27, 36]. (5) Compared to inositol nicotinate on
the basis of aspirin, Xuezhikang showed a signiﬁcant differ-
ence in the reduction of TC level (MD −1.05mmol/L;
95% CI −1.46 to −0.64; 1 trial, n = 105) [32].
3.3.7. Serum TG Level. There were 20 studies that reported
the level of TG (see Table 4), but one trial only reported the
serum lipid level of the treatment group [30]. (1) Com-
pared to no treatment with cointervention of conven-
tional therapy, Xuezhikang showed a reduction of TG level
(MD −0.49mmol/L; 95% CI −0.58 to −0.39; 7 trial, n =
412) [5, 6, 24, 29, 33, 38, 39]. (2) There were two trials that
reported Xuezhikang versus placebo on the basis of conven-
tional therapy, meta-analysis was not used for signiﬁcant
diﬀerence, and, in this comparison, Xuezhikang showed a
reduction of TG level (MD −0.17mmol/L; 95% CI −0.22 to
−0.12; 1 trial, n = 4870) [4] and (MD −1.29mmol/L; 95%
CI −1.57 to −1.01; 1 trial, n = 62) [35]. (3) There was no
signiﬁcant diﬀerence on serum TG level of Xuezhikang com-
paring to statins on the basis of conventional therapy (MD
−0.05mmol/L; 95% CI −0.12 to 0.02; 8 trial, n = 633) [21,
23–25, 28, 31, 37, 39]. (4) Compared with no treatment on
thebasisofﬂuvastatinandconventionaltherapy,Xuezhikang
showed a reduction of TG level (MD −0.27mmol/L; 95% CI
−0.35 to −0.19; 1 trial, n = 60) [36]. (5) Compared to inosi-
tol nicotinate on the basis of aspirin, Xuezhikang showed a
significant diﬀerence in the reduction of TG level (MD
−0.60mmol/L; 95% CI −0.95 to −0.25; 1 trial, n = 105)
[32].
3.3.8. Serum LDL-C Level. There were 21 studies that re-
ported the level of LDL-C (see Table 4), but one trial only
reported the serum lipid level of the treatment group [30].
(1) Compared to no treatment with cointervention of con-
ventional therapy, Xuezhikang showed a reduction of LDL-C
level (MD −0.78mmol/L; 95% CI −1.19 to −0.38; 7 trial,
n = 444) [5, 6, 24, 33, 34, 38, 39]. (2) There were two trials
that reported Xuezhikang versus placebo on the basis of con-
ventional therapy, meta-analysis was not used for significant
diﬀerence, and, in this comparison, Xuezhikang showed a
reductionofLDL-Clevel(MD −0.57mmol/L;95%CI −0.62
to −0.52;1trial,n = 4870)[4]and(MD−1.82mmol/L;95%
CI −2.01 to −1.63; 1 trial, n = 62) [35]. (3) There was no
signiﬁcant diﬀerence on serum LDL-C level of Xuezhikang
comparing to statins on the basis of conventional therapy
(MD 0.03mmol/L; 95% CI −0.10 to 0.25; 8 trial, n = 633)
[21, 23–25, 28, 31, 37, 39]. Because there was signiﬁcant
heterogeneity in the comparison, we examined the data
carefully and found that data of two trials deviated from
the others. After looking over the papers, one of the two
trials [26] with an unclear conventional therapy and the
other used Xuezhikang 300mg tid in the whole trial [37].6 Evidence-Based Complementary and Alternative Medicine
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Table 3: Analysis of clinical events.
Outcomes (comparisons) Treatment
group (n/N)
Control group
(n/N) RR 95% CI
(1) All-cause mortality
Xuezhikang capsule and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4] 126/2429 189/2441 0.67 [0.54,0.83]
(2) Mortality of CHD
(2.1) Xuezhikang capsule and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4]9 2 /2429 134/2441 0.69 [0.54,0.89]
(2.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Guan 2010 [22]1 /72 6/64 0.15 [0.02,1.20]
Lou et al. 2008 [28]1 /43 1/41 0.95 [0.06,14.75]
Overall(FEM,I2 = 13%) 0.26 [0.06,1.21]
(2.3) Xuezhikang and simvastatin and conventional therapy versus simvastatin and conventional therapy
Lin et al. 2009 [27]0 /24 1/24 0.33 [0.01,7.8]
(2.4) Xuezhikang and aspirin versus inositol nicotinate and aspirin
Wang and Xiao 2000 [32]1 /65 6/57 0.15 [0.02,1.18]
(3) Myocardial infarction
(3.1) Xuezhikang and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4]4 7 /2429 120/2441 0.39 [0.28,0.55]
(3.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Lou et al. 2008 [28]5 /43 5/41 0.95 [0.30,3.05]
(3.3) Xuezhikang and simvastatin and conventional therapy versus simvastatin and conventional therapy
Lin et al. 2009 [27]0 /24 2/24 0.2 [0.01,3.96]
(4) Revascularization
(4.1) Xuezhikang capsule and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4]7 3 /2429 110/2441 0.67 [0.50,0.895]
(4.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Lou et al. 2008 [28]6 /43 5/41 1.14 [0.38,3.46]
(5) Rehospitalization
(5.1) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Lou et al 2008 [28]1 5 /43 14/41 1.02 [0.57,1.84]
(5.2) Xuezhikang and simvastatin and conventional therapy versus simvastatin and conventional therapy
Lin et al. 2009 [27]1 /24 5/24 0.2 [0.03,1.59]
Sensitive analysis was used and got a similar conclusion
(MD 0.05mmol/L; 95% CI −0.09 to 0.19; 6 trial, n = 489)
after excluded the two trials [26, 37]. (4) Compared with
no treatment on the basis of statins and conventional ther-
apy, Xuezhikang showed a reduction of LDL-C level
(MD −0.44mmol/L; 95% CI −0.57 to −0.31; 2 trial, n =
108) [27, 36]. (5) Compared to inositol nicotinate on the
basis of aspirin, Xuezhikang showed a signiﬁcant diﬀerence
in the reduction of LDL-C level (MD −0.88mmol/L; 95% CI
−1.27 to −0.48; 1 trial, n = 105) [32].
3.3.9. Serum HDL-C Level. There were 19 studies that re-
ported the level of HDL-C (see Table 4), but one trial only
reported the serum lipid level of the treatment group [30].
(1) Compared to no treatment with cointervention of con-
ventional therapy, Xuezhikang showed a beneﬁcial eﬀect of
HDL-C level (MD 0.24mmol/L; 95% CI 0.08 to 0.40; 6
trial, n = 364) [5, 6, 24, 33, 34, 39]. (2) There were two
trials that reported Xuezhikang versus placebo on the basis
of conventional therapy, meta-analysis was not used for sig-
nificant diﬀerence, and, in this comparison, Xuezhikang
showed a beneﬁcial eﬀect of HDL-C level (MD 0.05mmol/L;
95% CI 0.03 to 0.07; 1 trial, n = 4870) [4]a n d( M D
0.48mmol/L; 95% CI 0.37 to 0.59; 1 trial, n = 62) [35].
(3) There was a lower eﬀect on serum HDL-C level of
Xuezhikangcomparingtostatinsonthebasisofconventional
therapy (MD −0.10mmol/L; 95% CI −0.19 to −0.01; 8 trial,
n = 633) [21, 23–25, 28, 31, 37, 39]. Because there was
signiﬁcant heterogeneity in the comparison, we examined
the data carefully and found that data of one trials deviated
from the others. After looking over the papers, we found that
the trial used Xuezhikang 300mg tid [37]. Sensitive analysis
was used and got a similar conclusion (MD −0.10mmol/L;
95% CI −0.11 to −0.08; 7 trial, n = 553) after excluded the
trial [37]. (4) Compared with no treatment on the basis ofEvidence-Based Complementary and Alternative Medicine 11
Table 4: Analysis of serum lipid level.
Serum lipid level
(comparison)
Intervention group Control group
Weight (%) MD 95% CI
Mean SD Mean SD
(1) TC (mmol/L)
(1.1) Xuezhikang and conventional therapy versus conventional therapy
Dai et al. 1999 [5] 5.41 0.87 6.54 0.89 11.40 −1.13 [−1.59,−0.67]
Huang et al. 2009 [24] 4.98 0.79 5.99 0.87 13.30 −1.01 [−1.36,−0.66]
Ma and Teng 2005 [29]5 .30 1.30 6.30 1.00 9.00 −1.00 [−1.61,−0.39]
Wang et al. 2004 [6] 4.33 0.96 6.30 0.79 11.10 −1.97 [−2.45,−1.49]
Xu 2005 [39] 5.49 1.12 6.20 0.93 6.60 −0.71 [−1.52,0.10]
Yan 2006 [34]4 .90 0.10 5.50 0.20 17.30 −0.60 [−0.67,−0.53]
Yan and Li 2007 [33]4 .90 0.13 5.93 0.23 17.00 −1.03 [−1.13,−0.93]
Zhou et al. 2003 [38]4 .30 0.54 4.84 0.78 14.30 −0.54 [−0.83,−0.25]
Overall(REM, I2 = 92%) 100 −0.97 [−1.24,−0.71]
(1.2) Xuezhikang and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4] 4.65 0.67 5.22 0.88 — −0.57 [−0.61,−0.53]
Yu et al. 2002 [35]4 .10 0.58 6.72 0.85 — −2.62 [−2.98,−2.26]
(1.3) Xuezhikang and conventional therapy versus statin and conventional therapy
(1.3.1) Xuezhikang and conventional therapy versus lovastatin and conventional therapy
Li et al. 2011 [26] 4.57 1.42 5.32 1.72 9.5 −0.75 [−1.52,0.02]
(1.3.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Huang et al. 2005 [23] 4.62 0.63 4.36 0.60 13.8 0.26 [0.02,0.50]
Jiang and Cai 2001 [25]5 . 1 9 0 .90 4.91 0.66 12.8 0.28 [−0.10,0.66]
Lou et al. 2008 [28] 5.4 0.12 5.40 0.11 14.4 0.00 [−0.05,0.05]
Subgroup Overall(REM, I2 = 69%) 0.14 [−0.08,0.35]
(1.3.3) Xuezhikang and conventional therapy versus ﬂuvastatin and conventional therapy
Gao and Liao 2003 [21] 4.05 0.74 3.63 0.59 13.1 0.42 [0.08,0.76]
(1.3.4) Xuezhikang and conventional therapy versus atorvastatin and conventional therapy
Shang 2007 [31] 4.65 0.79 4.88 0.85 13.5 −0.23 [−0.51,0.05]
Xu 2005 [39] 5.49 1.12 5.50 0.92 8.8 −0.01 [−0.86,0.84]
Zhang 2011 [37] 4.51 0.38 4.00 3.35 14.1 1.16 [0.99,1.33]
Subgroup Overall(REM, I2 = 97%) 0.33 [−0.77,1.43]
Aftersensitiveanalysis Subgroup Overall(FEM,I2 = 0%) −0.21 [−0.48,0.06]
Total Overall(REM, I2 = 96%) 0.19 [−0.22,0.59]
Aftersensitiveanalysis Total Overall(REM, I2 = 66%) 0.02 [−0.032,0.06]
(1.4) Xuezhikang and statin and conventional therapy versus statin and conventional therapy
(1.4.1) Xuezhikang and simvastatin and conventional therapy versus simvastatin and conventional therapy
Lin et al. 2009 [27]4 .30 0.71 5.00 0.81 35.6 −0.70 [−1.13,−0.27]
(1.4.2) Xuezhikang and ﬂuvastatin and conventional therapy versus ﬂuvastatin and conventional therapy
Zhang 2010 [36]4 .60 0.10 5.70 0.24 64.4 −1.10 [−1.19,−1.01]
Total Overall(REM, I2 = 68%) −0.96 [−1.33,−0.58]
(1.5) Xuezhikang and aspirin versus inositol nicotinate and aspirin
Wang and Xiao 2000 [32]5 .20 0.80 6.00 0.70 — −1.05 [−1.46,−0.64]
2. TG (mmol/L)
(2.1) Xuezhikang and conventional therapy versus conventional therapy
Dai et al. 1999 [5] 1.84 0.68 2.30 0.87 5.50 −0.48 [−0.87,−0.05]
Huang et al. 2009 [24] 1.49 0.31 1.97 0.37 44.40 −0.48 [−0.63,−0.33]
Ma and Teng 2005 [29]1 .70 0.40 2.30 0.70 10.50 −0.60 [−0.90,−0.30]12 Evidence-Based Complementary and Alternative Medicine
Table 4: Continued.
Serum lipid level
(comparison)
Intervention group Control group
Weight (%) MD 95% CI
Mean SD Mean SD
Wang et al. 2004 [6] 1.88 0.5 2.2 0.76 7.70 −0.32 [−0.67,0.03]
Xu 2005 [39]2 .70 0.92 2.52 1.67 0.90 0.18 [−0.87,1.23]
Yan and Li 2007 [33]1 . 5 4 0 .10 2.02 0.59 19.10 −0.48 [−0.70,−0.26]
Zhou et al. 2003 [38]1 .20 0.66 1.80 0.61 12.10 −0.60 [−0.88,−0.32]
Overall(FEM,I2 = 0%) 100% −0.49 [−0.58,−0.39]
(2.2) Xuezhikang and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4] 1.58 0.78 1.75 0.88 50.80 −0.17 [−0.22,−0.12]
Yu et al. 2002 [35] 2.22 0.71 3.51 0.36 49.20 −1.29 [−1.57,−1.01]
(2.3) Xuezhikang and conventional therapy versus statin and conventional therapy
(2.3.1) Xuezhikang and conventional therapy versus lovastatin and conventional therapy
Li et al. 2011 [26] 3.75 1.17 3.82 1.29 1.3 −0.07 [−0.67,0.53]
(2.3.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Huang et al. 2005 [23] 1.85 0.81 1.92 0.72 5.5 −0.07 [−0.37,0.23]
Jiang and Cai 2001 [25] 1.9 0.72 2.11 0.91 3.5 −0.21 [−0.58,0.16]
Lou et al. 2008 [28] 3.1 0.2 3.2 0.33 35.2 −0.11 [−0.21,0.00]
Subgroup Overall(FEM,I2 = 0%) 44.30 .11 [−0.21,−0.00]
(2.3.3) Xuezhikang and conventional therapy versus ﬂuvastatin and conventional therapy
Gao and Liao 2003 [21] 1.01 0.63 1.42 0.46 6.2 −0.41 [−0.69,−0.13]
(2.3.4) Xuezhikang and conventional therapy versus atorvastatin and conventional therapy
Shang 2007 [31] 1.61 0.53 1.57 0.55 14.1 0.04 [−0.15,0.23]
Xu 2005 [39] 2.7 0.92 2.22 0.73 1.0 0.48 [−0.21,1.17]
Zhang 2011 [37] 1.64 0.33 1.61 0.21 33.0 0.03 [−0.09,0.15]
Subgroup Overall(FEM,I2 = 0%) 48.10 .04 [−0.06,0.14]
Total Overall(FEM,I2 = 45%) 100 −0.05 [−0.12,0.02]
(2.4) Xuezhikang and statin and conventional therapy versus statin and conventional therapy
Zhang 2010 [36]1 . 5 8 0 .20 1.85 0.10 — −0.27 [−0.35,−0.19]
(2.5) Xuezhikang and aspirin versus inositol nicotinate and aspirin
Wang and Xiao 2000 [32]1 .70 0.90 2.30 0.90 — −0.60 [−0.95,−0.25]
(3) LDL-C (mmol/L)
(3.1) Xuezhikang and conventional therapy versus conventional therapy
Dai et al. 1999 [5] 3.42 0.96 3.93 0.81 13.50 −0.51 [−0.97,−0.05]
Huang et al. 2009 [24] 2.88 0.91 3.96 0.96 14.10 −1.08 [−1.48,−0.68]
Wang et al. 2004 [6] 2.21 0.4 3.87 0.56 15.20 −1.66 [−1.92,−1.40]
Xu 2005 [39] 2.82 0.95 3.7 0.95 10.50 −0.88 [−1.63,−0.13]
Yan 2006 [34] 2.89 0.44 2.9 0.6 15.50 −0.01 [−0.23,0.21]
Yan and Li 2007 [33]2 . 9 7 0 .10 3.88 0.20 16.20 −0.91 [−0.99,−0.83]
Zhou et al. 2003 [38] 3.22 0.6 3.68 0.71 15.00 −0.46 [−0.75,−0.17]
Overall(REM, I2 = 94%) 100 −0.78 [−1.19,−0.38]
(3.2) Xuezhikang and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4] 2.66 0.85 3.23 0.85 50.30 −0.57 [−0.62,−0.52]
Yu et al. 2002 [35] 2.48 0.39 4.30 0.39 49.70 −1.82 [−2.01,−1.63]
(3.3) Xuezhikang and conventional therapy versus statin and conventional therapy
(3.3.1) Xuezhikang and conventional therapy versus lovastatin and conventional therapy
Li et al. 2011 [26] 2.45 0.72 3.25 0.84 10.6 −0.80 [−1.18,0.42]Evidence-Based Complementary and Alternative Medicine 13
Table 4: Continued.
Serum lipid level
(comparison)
Intervention group Control group
Weight (%) MD 95% CI
Mean SD Mean SD
(3.3.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Huang et al. 2005 [23] 2.68 0.55 2.52 0.49 13.9 0.16 [−0.04,0.36]
Jiang and Cai 2001 [25] 3.1 0.41 2.90 0.90 12.2 0.20 [−0.10,0.50]
Lou et al. 2008 [28] 2.8 0.09 2.9 0.1 15.7 −0.10 [−0.14,−0.06]
Subtotal Overall(REM, I2 = 79%) 41.80 .06 [−0.17,0.28]
(3.3.3) Xuezhikang and conventional therapy versus ﬂuvastatin and conventional therapy
Gao and Liao 2003 [21] 2.13 0.58 2.08 0.61 12.2 0.05 [−0.25,0.35]
(3.3.4) Xuezhikang and conventional therapy versus atorvastatin and conventional therapy
Shang 2007 [31] 2.54 0.56 2.44 0.52 14.2 0.10 [−0.09,0.29]
Xu 2005 [39] 2.82 0.95 2.93 0.52 6.9 −0.11 [−0.74,0.52]
Zhang 2011 [37] 3.04 0.48 2.51 0.32 14.3 0.53 [0.35,0.71]
Subtotal Overall(REM,I2 = 84%) 35.40 .23 [−0.14,0.60]
Aftersensitiveanalysis Subtotal Overall(FEM,I2 = 0%) 0.08 [−0.10,0.26]
Total Overall(REM,I2 = 90%) 0.03 [−0.10,0.25]
Aftersensitiveanalysis Total Overall(REM,I2 = 64%) 0.05 [−0.09,0.19]
(3.4) Xuezhikang and statin and conventional therapy versus statin and conventional therapy
(3.4.1) Xuezhikang and simvastatin and conventional therapy versus simvastatin and conventional therapy
Lin et al. 2009 [27]2 .10 0.78 2.60 0.80 8.4 −0.50 [−0.95,−0.05]
(3.4.2) Xuezhikang and ﬂuvastatin and conventional therapy versus ﬂuvastatin and conventional therapy
Zhang 2010 [36] 2.87 0.32 3.30 0.20 91.6 −0.43 [−0.57,−0.29]
Total Overall(FEM,I2 = 0%) −0.44 [−0.57,−0.31]
(3.5) Xuezhikang and aspirin versus inositol nicotinate and aspirin
Wang and Xiao 2000 [32]2 .70 0.70 3.40 0.90 100 −0.88 [−1.27,−0.48]
(4) HDL-C (mmol/L)
(4.1) Xuezhikang and conventional therapy versus conventional therapy
Dai et al. 1999 [5] 1.71 0.42 1.04 0.49 14.60 0.67 [−0.43,0.91]
Huang et al. 2009 [24] 1.12 0.3 0.82 0.2 19.50 0.3 [0.19,0.41]
Wang et al. 2004 [6] 1.44 0.38 1.31 0.27 17.00 0.13 [−0.05,0.31]
Xu 2005 [39] 1.67 0.51 1.68 0.75 7.10 −0.01 [−0.51,0.49]
Yan 2006 [34]1 . 0 4 0 .10 1.04 0.20 20.60 0.00 [−0.07,0.07]
Yan and Li 2007 [33] 1.09 0.09 0.80 0.07 21.10 0.29 [0.25,0.33]
Overall(REM,I2 = 93%) 100 0.24 [0.08,0.40]
(4.2) Xuezhikang and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4] 1.24 0.31 1.19 0.31 50.80 0.05 [0.03,0.07]
Yu et al. 2002 [35] 1.45 0.25 0.97 0.19 49.20 0.48 [0.37,0.59]
(4.3) Xuezhikang and conventional therapy versus statin and conventional therapy
(4.3.1) Xuezhikang and conventional therapy versus lovastatin and conventional therapy
Li et al. 2011 [26] 1.12 0.38 1.06 0.36 11.4 0.16 [−0.33,0.65]
(4.3.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Huang et al. 2005 [23] 1.85 0.81 1.92 0.72 6.4 −0.09 [−0.47,0.29]
Jiang and Cai 2001 [25] 1.16 0.17 1.21 0.12 19.0 −0.05 [−0.12,0.02]
Lou et al. 2008 [28] 0.8 0.03 0.9 0.03 21.4 −0.10 [−0.11,−0.09]
Overall(FEM,I2 = 0%) −0.10 [−0.11,−0.09]
(4.3.3) Xuezhikang and conventional therapy versus ﬂuvastatin and conventional therapy
Gao and Liao 2003 [21] 1.14 0.27 1.30 0.45 11 −0.16 [−0.35,0.03]14 Evidence-Based Complementary and Alternative Medicine
Table 4: Continued.
Serum lipid level
(comparison)
Intervention group Control group
Weight (%) MD 95% CI
Mean SD Mean SD
(4.3.4) Xuezhikang and conventional therapy versus atorvastatin and conventional therapy
Shang 2007 [31] 1.45 0.41 1.44 0.33 14.9 0.01 [−0.12,0.14]
Xu 2005 [39] 1.67 0.51 1.53 0.48 3.8 0.14 [−0.27,0.55]
Zhang 2011 [37] 1.09 0.48 1.62 0.27 12.1 −0.53 [−0.70,−0.36]
Subtotal Overall(REM,I2 = 93%) 30.9 −0.15 [−0.57,0.28]
Aftersensitiveanalysis Subtotal Overall(FEM,I2 = 0%) 0.02 [−0.10,0.14]
Total Overall(REM, I2 = 79%) −0.10 [−0.19,−0.01]
Aftersensitiveanalysis Total Overall(FEM,I2 = 35%) −0.10 [−0.11,−0.08]
(4.4) Xuezhikang and ﬂuvastatin and conventional therapy versus ﬂuvastatin and conventional therapy
Zhang 2010 [36] 0.97 0.28 0.82 0.06 100 0.15 [0.05,0.25]
(4.5) Xuezhikang and aspirin versus inositol nicotinate and aspirin
Wang and Xiao 2000 [32] 0.95 0.22 0.91 0.25 100 0.17 [−0.21,0.55]
Note: FEM: ﬁxed eﬀects model; REM: random eﬀects model.
ﬂuvastatin and conventional therapy, Xuezhikang showed a
beneﬁcial of HDL-C level (MD 0.15mmol/L; 95% CI 0.05
to 0.25; 1 trial, n = 60) [36]. (5) Compared with inositol
nicotinate on the basis of aspirin, Xuezhikang showed no
signiﬁcant diﬀerence on HDL-C level (MD 0.17mmol/L;
95% CI −0.21 to 0.55; 1 trial, n = 105) [32].
3.4. Publication Bias. A funnel plot analysis of the 8 trials in
comparison of Xuezhikang and conventional therapy versus
conventional therapy on serum TC level was conducted and
shown in Figure 3.
3.5. Adverse Events. There were 17 trials that reported
adverse events (Ads); see Table 5. 4 of the 17 trials [5, 24,
33, 37] indicated no Ads in the duration of treatment, and
2t r i a l s[ 23, 34] only introduced that there was no diﬀerence
of the two groups. The most commonly reported Ads in the
10 trials were intestinal disturbance (abdominal distension,
constipation, and diarrhea), dizziness, high serum alanine
aminotransferase (ALT), high serum creatine kinase (CK),
high serum creatinine, high blood urea nitrogen (BUN), and
skin itch. All of Ads were not signiﬁcantly diﬀerent between
the Xuezhikang group and control group. One trial [4]r e -
ported that there was signiﬁcant diﬀerence between the two
groups on sexual dysfunction (P = 0.0253) in the paper,
but after we import the data into Revman 5.1, there was no
diﬀerence (RR 0.09, 95% CI [0.01,1.64]) between the two
groups. CCSPS [4] reported the clinical total Ads number
(intestinal disturbance, allergy and et al.) in each group
(treatment group 43; control group 39), and there was no
signiﬁcant diﬀerence between the two groups, this trial also
reported death in other reason, which was introduced in all-
cause mortality, and the diﬀerence between the two groups
was not signiﬁcant.
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Figure 3: The funnel plot for assessing reporting bias.
4. Discussion
This systematic review included 22 randomized trials and
a total of 6520 participants. Xuezhikang showed signiﬁcant
beneﬁt on the incidence of all-cause deaths, CHD deaths,
myocardial infarction, and revascularization as compared
with placebo or no intervention based on conventional treat-
ment for CHD. It remarkably lowered TC, TG, and LDL-C
as compared with the placebo or inositol nicotinate group,
which was similar to statins group. Xuezhikang also signif-
icantly raised HDL-C compared to placebo or no interven-
tion, which was similar to inositol nicotinate and slightly
inferior to statins. The incidence of adverse events did not
diﬀer between the Xuezhikang and control group. The re-
sults showed the comprehensive lipid-regulating eﬀect of
Xuezhikang and indicated that it was safe and eﬀective in
reducing cardiovascular events in CHD patients complicated
by dyslipidemia.Evidence-Based Complementary and Alternative Medicine 15
Table 5: Adverse Events.
Ads/ID Comparison Treatment
group (n/N)
Control
group (n/N) RR 95% CI
Loss of followup
Guan 2010 [22] Xuezhikang versus simvastatin 16 (72) 15 (64) 0.95 [0.51,1.76]
CCSPS 2005 [4] Xuezhikang and conventional therapy versus
placebo and conventional therapy 37 (2441) 28 (2429) 1.31 [0.81,2.14]
Ma and Teng 2005 [29] Xuezhikang and conventional therapy versus
conventional therapy 1 (29) No report
Intestinal disturbance
Guan 2010 [22] Xuezhikang versus simvastatin 5 (72) 2 (64) 2.22 [0.45,11.06]
Ma and Teng 2005 [29] Xuezhikang and conventional therapy versus
conventional therapy 2 (29) No report
Wang et al. 2004 [6] Xuezhikang and conventional therapy versus
conventional therapy 2 (26) No report
Jiang and Cai 2001 [25] Xuezhikang and conventional therapy versus
simvastatin and conventional therapy 0 (30) 1 (45) 0.49 [0.02,11.75]
Shang 2007 [31] Xuezhikang and conventional therapy versus
atorvastatin and conventional therapy No report 1 (65)
Wang and Xiao 2000 [32] Xuezhikang and aspirin versus inositol
nicotinate and aspirin 5 (65) 2 (57) 2.19 [0.44,10.87]
Headache
Jiang and Cai 2001 [25] Xuezhikang and conventional therapy versus
simvastatin and conventional therapy 1 (30) 0 (45) 4.45 [0.19,105.77]
Dizziness
Guan 2010 [22] Xuezhikang and conventional therapy versus
simvastatin and conventional therapy 0 (72) 10 (64) 0.04 [0.00,0.71]
Jiang and Cai 2001 [25] Xuezhikang and conventional therapy versus
simvastatin and conventional therapy 1 (30) 1 (45) 1.5 [0.10,23.07]
Overall(REM,I2 = 72%) 0.26 [0.01,10.49]
Skin itech
Guan 2010 [22] Xuezhikang versus simvastatin 0 (72) 3 (64) 0.13 [0.01,2.42]
Wang and Xiao 2000 [32] Xuezhikang and aspirin versus inositol
nicotinate and aspirin 0 (65) 3 (57) 0.13 [0.01,2.38]
Sexual dysfunction
CCSPS 2005 [4] Xuezhikang and conventional therapy versus
placebo and conventional therapy 0 (1996) 5 (1990) 0.09 [0.01,1.64]
High serum ALT
CCSPS 2005 [4] Xuezhikang and conventional therapy versus
placebo and conventional therapy 15 (2441) 22 (2429) 0.68 [0.35,1.30]
Lou et al. 2008 [28] Xuezhikang and conventional therapy versus
simvastatin and conventional therapy No report 1 (41)
High serum CK
CCSPS 2005 [4] Xuezhikang and conventional therapy versus
placebo and conventional therapy 0 (2441) 3 (2429) 0.14 [0.01,2.75]
High serum CR
CCSPS 2005 [4] Xuezhikang and conventional therapy versus
placebo and conventional therapy 104 (2441) 89 (2429) 1.16 [0.88,1.53]
High BUN
CCSPS 2005 [4] Xuezhikang and conventional therapy versus
placebo and conventional therapy 124 (2441) 131 (2429) 0.94 [0.74,1.20]16 Evidence-Based Complementary and Alternative Medicine
Due to the potential side eﬀects of statins, natural pro-
ducts have raised more and more attention worldwide. The
health-enhancing qualities of red yeast rice have been intro-
duced and used in China for over two thousand years. A
meta-analysisofrandomizedcontrolledtrialsonChinesered
yeast rice for primary hyperlipidemia showed a signiﬁcant
reduction in serum levels of TC, TG, LDL-C, and an increase
in HDL-C levels compared with placebo. The lipid modi-
ﬁcation eﬀects appeared to be similar to pravastatin, sim-
vastatin, atorvastatin, lovastatin, or ﬂuvastatin [40]. A latest
systematic review also indicated the beneﬁcial eﬀects of
Xuezhikang in the treatment of hyperlipidemia [2]. The
lipid-regulating eﬀects of Xuezhikang in these reviews were
similar to our ﬁndings. In addition, some cardioprotective
eﬀects of Xuezhikang have been investigated in recent years
[41–43]. We further demonstrated the beneﬁt of Xuezhikang
in reducing cardiovascular events in CHD patients com-
plicated by dyslipidemia, or even CHD with normal blood
lipid level but failed to reach the lipid-lowering goal.
However, current evidence comparing the eﬀectiveness and
Ads between Xuezhikang and statins in CHD patients was
not enough to draw the conclusion.
It is worth mentioning China Coronary Secondary Pre-
vention Study (CCSPS) [4], which was the largest RCT in-
cluded in this review. This multicenter, randomized, and
placebo-controlled study aimed to demonstrate the long-
term therapeutic eﬀect and safety of Xuezhikang in the sec-
ond prevention of CHD. 4870 cases in 66 medical centers
were enrolled and followed up for an average of 4.5 years.
The results showed that Xuezhikang signiﬁcantly decreased
the recurrence of coronary events and the occurrence of new
cardiovascular events and deaths, improved lipoprotein reg-
ulation, and was safe and well tolerated [4]. The study was
the ﬁrst large-scale clinical trial in eastern population who
suﬀered from mild or moderate degree of hyperlipidemia
and previous MI. The CCSPS study is quite comparable with
(Cholesterol and Recurrent Events) CAREs study [44]i n
termsofthetargetpopulation,samplesize,baselinelipidand
follow-up time. However, Xuezhikang in CCSPS lowered less
lipid level as compared with pravastatin in CARE but seemed
to gain more beneﬁt in reducing the cardiovascular events.
Since the eﬀect of Xuezhikang is partially attributed to the
presence of statins, it has been hypothesized that relatively
high concentrations of unsaturated fatty acids and other nat-
ural compounds found in Xuezhikang may work in concert
with the statins to provide additional health beneﬁts [45].
Therefore,alarge-scaleRCTcomparingdirectlytheeﬀective-
ness and safety of long-term use of Xuezhikang and statins is
warranted.
Before recommending the conclusion of this review to
clinical practicers, we have to consider the following weak-
nesses in this review.(1) Firstly, the “randomization” was not
clear in most of the trials for insuﬃcient reporting of gen-
eration methods of the allocation sequence and allocation
concealment. Most trials stated only that patients were ran-
domly assigned. (2) Secondly, most of trials did not intro-
duce double blind in this review, and only one trial intro-
duced blinding of outcome assessment, therefore, in non-
placebo-controlled and non-double-blind trials, placebo
eﬀects may add to the complexity of interpreting the
conclusion. (3) Most of the trials did not introduce the study
plan, attrition bias and selective reporting bias might exist in
this conclusion. (4) Thirdly, funnel plot indicated that publi-
cation bias would exist in this review. The reasons are as fol-
lows. We only selected trials published in Chinese and Eng-
lish, and trials published in other language or originated
from other countries might be omitted; we only identiﬁed
unpublished studies from conference paper or academic the-
sis, and negative trials might not be reported and induced
publication bias.
Therefore, further rigorously designed trials are still
needed before Xuezhikang could be recommended to pa-
tients with CHD complicated by dyslipidemia, especially as
an alternative to statins. Whether or not long-term medica-
tion of Xuezhikang could provide similar beneﬁt to statins
for CHD secondary prevention with less adverse events? Is it
related to the target lipid value? All of these need to be an-
swered in the future investigation.
5. Conclusion
Xuezhikang showed a comprehensive lipid-regulating eﬀect
and was safe and eﬀective in reducing CHD mortality, the
incidence of myocardial infarction and revascularization in
CHD patients complicated by dyslipidemia. However, the
small sample size and potential bias of most trials inﬂuence
the convincingness of this conclusion. Before recommending
Xuezhikang as an alternative to statins in CHD patients,
morerigoroustrialswithhighqualityareneededtogivehigh
level of evidence, especially for comparing the eﬀectiveness
and safety between Xuezhikang and statins.
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